ELI LILLY CFO SAYS INJECTABLE GLP-1 DRUGS REMAIN KEY GROWTH DRIVER, ACCOUNT FOR THREE OUT OF FOUR NEW PATIENT STARTS: CONF CALL

Reuters · 3d ago

Please log in to view news